Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 2
1949 1
1950 1
1951 1
1952 1
1953 1
1954 2
1955 1
1962 1
1966 1
1969 1
1971 1
1972 1
1974 1
1975 2
1976 2
1977 1
1978 4
1979 3
1980 2
1983 4
1984 5
1985 5
1986 6
1987 5
1988 9
1989 12
1990 7
1991 16
1992 20
1993 36
1994 28
1995 31
1996 34
1997 55
1998 57
1999 70
2000 60
2001 79
2002 85
2003 74
2004 111
2005 129
2006 131
2007 159
2008 181
2009 192
2010 195
2011 239
2012 245
2013 280
2014 266
2015 286
2016 313
2017 319
2018 320
2019 392
2020 437
2021 468
2022 476
2023 432
2024 412
2025 425
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,443 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Finn RS, et al. Among authors: cheng al. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Among authors: cheng al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: cheng al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
2024 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces.
Greif R, Bray JE, Djärv T, Drennan IR, Liley HG, Ng KC, Cheng A, Douma MJ, Scholefield BR, Smyth M, Weiner G, Abelairas-Gómez C, Acworth J, Anderson N, Atkins DL, Berry DC, Bhanji F, Böttiger BW, Bradley RN, Breckwoldt J, Carlson JN, Cassan P, Chang WT, Charlton NP, Phil Chung S, Considine J, Cortegiani A, Costa-Nobre DT, Couper K, Couto TB, Dainty KN, Dassanayake V, Davis PG, Dawson JA, de Caen AR, Deakin CD, Debaty G, Del Castillo J, Dewan M, Dicker B, Djakow J, Donoghue AJ, Eastwood K, El-Naggar W, Escalante-Kanashiro R, Fabres J, Farquharson B, Fawke J, de Almeida MF, Fernando SM, Finan E, Finn J, Flores GE, Foglia EE, Folke F, Goolsby CA, Granfeldt A, Guerguerian AM, Guinsburg R, Hansen CM, Hatanaka T, Hirsch KG, Holmberg MJ, Hooper S, Hoover AV, Hsieh MJ, Ikeyama T, Isayama T, Johnson NJ, Josephsen J, Katheria A, Kawakami MD, Kleinman M, Kloeck D, Ko YC, Kudenchuk P, Kule A, Kurosawa H, Laermans J, Lagina A, Lauridsen KG, Lavonas EJ, Lee HC, Han Lim S, Lin Y, Lockey AS, Lopez-Herce J, Lukas G, Macneil F, Maconochie IK, Madar J, Martinez-Mejas A, Masterson S, Matsuyama T, Mausling R, McKinlay CJD, Meyran D, Montgomery W, Morley PT, Morrison LJ, Moskowitz AL, Myburgh M,… See abstract for full author list ➔ Greif R, et al. Among authors: cheng a. Circulation. 2024 Dec 10;150(24):e580-e687. doi: 10.1161/CIR.0000000000001288. Epub 2024 Nov 14. Circulation. 2024. PMID: 39540293 Free article. Review.
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
Noureddin M, Rinella ME, Chalasani NP, Neff GW, Lucas KJ, Rodriguez ME, Rudraraju M, Patil R, Behling C, Burch M, Chan DC, Tillman EJ, Zari A, de Temple B, Shringarpure R, Jain M, Rolph T, Cheng A, Yale K. Noureddin M, et al. Among authors: cheng a. N Engl J Med. 2025 Jun 26;392(24):2413-2424. doi: 10.1056/NEJMoa2502242. Epub 2025 May 9. N Engl J Med. 2025. PMID: 40341827 Clinical Trial.
Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study.
Xiao D, Chen Z, Wu S, Huang K, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Yao W, Sun T, Shan G, Yang T, Lin Y, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Hou G, Zhou Y, Li W, Ding L, Wang H, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Liang L, Liu Z, Zhang X, Cheng A, Cao B, Dai H, Chung KF, He J, Wang C; China Pulmonary Health Study Group. Xiao D, et al. Among authors: cheng a. Lancet Respir Med. 2020 Nov;8(11):1081-1093. doi: 10.1016/S2213-2600(20)30155-7. Epub 2020 Jun 26. Lancet Respir Med. 2020. PMID: 32598906
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa L, Kao JH, Zhang BH, Llovet JM, Bruix J, Yip TC, Wong VW, Wong GL, Chan LL, Liu MQ, Gao Q, Shen F, Kelley RK, Cheng AL, Kurosaki M, Toyoda H, Chen WX, Murakami T, Liang P, Zucman-Rossi J, Minami Y, Miyayama S, Wang K, Man K, Hasegawa K, Li Q, Tsuchiya K, Xu L, Chew V, Chow P, Hoshida Y, Lujambio A, Ng IO, Sakamoto M, Park YN, Yau T, Kudo M, Fan J, Zhou J. Chan SL, et al. Among authors: cheng al. Lancet. 2025 Aug 16;406(10504):731-778. doi: 10.1016/S0140-6736(25)01042-6. Epub 2025 Jul 28. Lancet. 2025. PMID: 40744051 Review. No abstract available.
Investigating the effect of enhanced cleaning and disinfection of shared medical equipment on health-care-associated infections in Australia (CLEEN): a stepped-wedge, cluster randomised, controlled trial.
Browne K, White NM, Russo PL, Cheng AC, Stewardson AJ, Matterson G, Tehan PE, Graham K, Amin M, Northcote M, Kiernan M, King J, Brain D, Mitchell BG. Browne K, et al. Among authors: cheng ac. Lancet Infect Dis. 2024 Dec;24(12):1347-1356. doi: 10.1016/S1473-3099(24)00399-2. Epub 2024 Aug 13. Lancet Infect Dis. 2024. PMID: 39151440 Clinical Trial.
6,443 results